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Abstract: Granulocytic myeloid-derived suppressor cells (Gr-MDSCs) promote immune evasion
and resistance to immunotherapeutics in a variety of malignancies. Our previous study showed
that dual PI3K/mTOR inhibitor Dactolisib impaired the viability and immunosuppressive function
of Gr-MDSCs, and significantly synergized with immune checkpoint blockade (ICB) antibodies
targeting PD1 and CTLA4 to eradicate metastatic castration-resistant prostate cancer (CRPC) in a
preclinical transgenic mouse model. On the contrary, tyrosine kinase inhibitor Dasatinib diminished
tumor-infiltrating T lymphocytes and showed no synergic activity with ICB. The understanding
of the distinct effects of Dactolisib and Dasatinib on Gr-MDSCs, T cells and prostate neoplastic
cells is inadequate, limiting the clinical translation of the combination immunotherapy. To address
this question, we applied Reverse Phase Protein Array (RPPA) to profile 297 proteins and protein
phosphorylation sites of Gr-MDSCs, T cells and prostate cancer cells isolated from the CRPC model.
We found cell type-specific protein expression patterns and highly selective targets by the two drugs,
including preferential inhibition of phospho-4E-BP1 in Gr-MDSCs by Dactolisib and preferential
suppression of phospho-Src and phospho-p38 MAPK in T cells. Furthermore, transcriptomic profiling
of Gr-MDSCs treated with the two inhibitors revealed downregulation of mitochondrial respiration
pathways by Dactolisib but not Dasatinib. Overall, these results provide important mechanistic
insight into the efficacious combination of Dactolisib and ICB as well as the detrimental effect of
Dasatinib on anti-tumor immunity.
Keywords: granulocytic myeloid-derived suppressor cells; immune checkpoint blockade;
combination immunotherapy; castration-resistant prostate cancer; Dactolisib; Dasatinib; reverse
phase protein array; PI3K/mTOR; Src; mitochondrial respiration
1. Introduction
The microenvironment of solid tumors is comprised of a complex mixture of epithelial cells, stromal
cells, endothelial cells and immune cells [1]. Among tumor-infiltrating immune cells, myeloid-derived
suppressor cells (MDSCs) represent a cell type gaining tremendous interest in recent years. MDSCs
are a heterogeneous population of immature myeloid cells with differentiation programs partially
blocked in pathological conditions such as cancer [2]. MDSCs can be phenotypically divided into
granulocytic (Gr-MDSCs, CD11b+ Ly6G+ Ly6Clow in mouse, CD11b+ CD14− CD15+ CD66b+ in human)
and monocytic (Mo-MDSCs, CD11b+ Ly6G− Ly6Chigh in mouse, CD11b+ CD14+ CD15− HLA-DR−/low
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in human) subpopulations [3]. Through inhibition of T cells, especially cytotoxic T lymphocytes (CTLs),
MDSCs play important tumor-promoting roles and maintain a state of immunological anergy and
tolerance [4,5]. MDSCs can suppress T cell activity through deprivation of nutrients, such as L-arginine
and L-cysteine, and interference with T cell receptor function and downstream signal pathways via
reactive oxygen species and reactive nitrogen species [6,7].
Immunosuppression by MDSCs may have profound implications in cancer immunotherapy.
Among the immunotherapeutic modalities, immune checkpoint blockade (ICB) to reinvigorate CTLs
using antibodies targeting CTLA4 or PD1/PD-L1 generates durable therapeutic responses in patients
across a variety of cancer types [8,9]. However, some cancers such as metastatic castration-resistant
prostate cancer (CRPC) show de novo resistance to ICB [10,11]. Prostate cancer (PCa) microenvironment
is highly immunosuppressive and infiltrated with abundant MDSCs, especially Gr-MDSCs as the
predominant population in both mouse models and clinical PCa [12–15], suggesting Gr-MDSCs as the
major barrier to block the efficacy of ICB.
Previously, we reported that, in the PB-Cre+ PtenL/L p53L/L Smad4L/L mTmGL/+ LSL-LucL/+ (CPPSML)
transgenic mouse model of metastatic CRPC, ICB therapy could be effectively improved through
pharmacological targeting of Gr-MDSCs [16]. Specifically, while CRPC developed in the CPPSML
model responded poorly to either the ICB antibody cocktail composed of anti-PD1 and anti-CTLA4 or
the PI3K/mTOR dual inhibitor Dactolisib (as known as BEZ235), the combination of these agents elicited
a strong synergistic effect on eradicating both the primary and metastatic CRPC [16]. Mechanistically,
Dactolisib inhibited the viability and immunosuppressive activity of Gr-MDSCs through silencing
the PI3K signaling and upregulation of interleukin-1 receptor antagonist while sparing the activity of
CD4+ and CD8+ T cells, thus creating a tumor microenvironment permissive to the effect from ICB
on unleashing CTLs. On the contrary, the tyrosine kinase inhibitor (TKi) Dasatinib was incapable
of cooperating with ICB because of its potent activity to diminish tumor-infiltrating T cells [16],
consistent with the reported Dasatinib inhibition of T cell receptor-mediated signal transduction and
proliferation [17].
Despite this previous study, we have inadequate understanding of the differential effect of
Dactolisib and Dasatinib on Gr-MDSCs, T cells and PCa cells at the protein levels. To address this,
we isolated these cell types from the CPPSML model, applied a short in vitro treatment (2 h) with
Dactolisib or Dasatinib, and subjected the cells to the targeted proteomic profiling with Reverse
Phase Protein Array (RPPA). RPPA technology is a high-throughput dot-blot immunoassay to provide
semi-quantitative measurement of total protein levels and post-translational modifications (PTMs)
across a variety of signaling pathways involved in cancer and immunology [18]. In our study, the RPPA
platform included 297 unique antibodies, which demonstrated distinct protein expression patterns for
Gr-MDSCs, T cells and PCa cells. We found that each cell type displayed specific responses to Dactolisib
and Dasatinib at the protein level, validated further by western blot. Furthermore, to examine the effect
of the two drugs on the transcriptome of Gr-MDSCs, the 6 h treated cells were profiled by microarray,
which revealed downregulation of mitochondria-related pathways by Dactolisib but not Dasatinib
treatment. These results together provide critical insights into the disparate effects of these two drugs
when used together with ICB in metastatic CRPC.
2. Results
2.1. Distinct Protein Expression Pattern by PCa Cells, T Cells and Gr-MDSCs in a Mouse CRPC Model
In the same procedure as we reported [16], we induced CRPC formation in CPPSML model by
surgically castrating CPPSML males when prostate tumors reached 150 mm3 measured by magnetic
resonance imaging, followed by feeding the mice with an enzalutamide-admixed diet for 4 weeks. At
this stage, the mice were euthanized and the prostate tumors were dissected and digested for isolation of
primary PCa cells using fluorescence-activated cell sorting (FACS) of GFP+ CD45− cells, or isolation of
tumor-infiltrating Gr-MDSCs using magnetic-activated cell sorting (MACS) of CD11b+ Ly6G+ Ly6Clow
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cells. From the same mice, total T cells were isolated from the spleen using MACS. PCa cells were
cultured for 2–3 passages as adherent primary cells before inhibitor treatment, whereas Gr-MDSCs and
T cells were treated immediately after isolation to maximize survival. Cells were treated with DMSO
(control), Dactolisib or Dasatinib at various concentrations for 2 h before harvest for the RPPA workflow
(Figure 1A, Supplementary Table S1). Unsupervised clustering of the log2 transformed RPPA signals
of untreated or DMSO-treated cell samples (6 PCa cell samples, 6 Gr-MDSC samples, 4 T cell samples)
grouped the cells in accurate concordance with their cell types (Figure 1B), indicating the distinct
expression pattern of the three cell types. It is readily noticeable that T cells and Gr-MDSCs share more
similarity in comparison with PCa cells, consistent with the fact that the former two cell types are
both descendants of hematopoietic lineage, whereas PCa cells are of epithelial lineage. Differential
expression analysis of PCa cells, T cells and Gr-MDSCs, shown in volcano plots, demonstrate interesting
patterns (Figure 1C, Supplementary Table S2–S4). For example, Gr-MDSCs have a unique high level
of P-cadherin over both T cells and PCa cells (Gr-MDSC/T = 16.6, Gr-MDSC/PCa = 8.89). T cells
highly express Histone-H3 and Lck compared with Gr-MDSCs (T/Gr-MDSC for Histone-H3 = 3.04,
T/Gr-MDSC for Lck = 2.68) and PCa cells (T/PCa for Histone-H3 = 7.76, T/PCa for Lck = 7.01). PCa
cells have a higher abundance of a number of proteins and PTMs compared with Gr-MDSCs and T
cells, such as E-cadherin, Connexin-43, ARID1A, eIF4G, HES1, phospho-Akt (Ser473), phospho-S6
(Ser235/236, Ser240/244), Phospho-NDRG1 (Thr346), phospho-YAP (Ser127), and TAZ (fold change > 5).
Enrichment of phospho-Akt and phospho-S6 in PCa cells is consistent with the prostate-specific
deletion of Pten in the CPPSML model.
2.2. Differential Effect of Dactolisib and Dasatinib on Protein Phosphorylation in PCa Cells, T cells
and Gr-MDSCs
To identify the treatment effect of Dactolisib and Dasatinib on specific proteins or PTMs in the
three cell types, we generated supervised clustering trees of the normalized RPPA data of the control
(untreated and DMSO-treated) and inhibitor-treated (Dactolisib or Dasatinib) samples. Dysregulated
targets emerged in cell type-specific and inhibitor-specific manners. For Gr-MDSCs, among the 297
unique antibodies, only phospho-4E-BP1 (Thr37/46) was consistently decreased by Dactolisib, but it
was unaffected by Dasatinib (Figure 2A), consistent with the biological effect of Dactolisib on inhibiting
PI3K/mTOR signaling. In a similar manner, Ser235/236 and Ser240/244 phosphorylation of S6 in
PCa cells were downregulated by Dactolisib but remained unchanged under Dasatinib treatment
(Figure 2B). By contrast, phospho-Src (Tyr527) was only downregulated by Dasatinib in PCa cells
(Figure 2B), corresponding to the activity of Dasatinib as a Src inhibitor [19]. For T cells, Dasatinib, but
not Dactolisib, effectively downregulated phospho-Src (Tyr416 and Tyr527) and phospho-p38 MAPK
(Thr180/182) (Figure 2C). Together, these results demonstrate that with a short time treatment (2 h),
Dactolisib and Dasatinib attenuated specific signaling targets of the PI3K/mTOR or Src/MAPK pathway,
respectively. It is interesting to note that the majority of the surveyed proteins and PTMs remained
largely unchanged by the inhibitors in all three cell types.
2.3. Cell Type-Specific Downregulation of Phosphorylation Levels of S6, 4E-BP1, Src and p38 MAPK by
Dactolisib and Dasatinib
In order to compare the dose-dependent effect of Dactolisib and Dasatinib on different cell types,
we calculated the ratio of phosphorylated over total protein RPPA signal intensity for S6, 4E-BP1, Src
and p38 MAPK (identified above as differentially regulated by the inhibitors) and plotted for each
cell type at the tested concentrations (Figure 3). For each cell type, the ratio at different inhibitor
concentrations was normalized to DMSO control (0 µM) for each cell type and expressed as percentages
to help show the relative changes (Figure 3).
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Figure 1. RPPA profiling of PCa cells, Gr-MDSCs and T cells of the CPPSML model of CRPC.
(A) Workflow of cell isolation and RPPA. The figure was created with BioRender.com. (B) Unsupervised
hierarchical clustering of PCa cells, T cells and Gr-MDSCs (untreated or DMSO-treated) with normalized
RPPA signals. Each row represents a biological replicate sample and each column corresponds to
an antibody in the RPPA array. (C) Volcano plots showing the pairwise fold change comparisons
of the normalized protein or PTM levels among the three cell types. p values were calculated by
Student’s t-test. Arrows help to pinpoint proteins of interest of whose labels were partly overlapped
with adjacent labels.
For the ratio of phospho-S6 / total S6, Dactolisib dramatically decreased phosphorylation of
Ser235/236 (100% at 0 µM, 10.5% at 0.1 µM) and Ser240/244 (100% at 0 µM, 20% at 0.1 µM) only in PCa
cells, but not in T cells or Gr-MDSCs (Figure 3A). On the other hand, Dasatinib caused little effect on
phospho-S6 in either cell type. The higher basal level of phospho-S6 and higher sensitivity to Dactolisib
in PCa cells compared with T cells or Gr-MDSCs is consistent with the Pten-deficient status of PCa cells.
For the ratio of phospho-4E-BP1 / total 4E-BP1, Dactolisib mildly repressed phosphorylation at
Thr37/46 and Ser65 in all cell types (100% at 0 µM, >50% at 0.1 µM), except for Thr37/46 in Gr-MDSCs
(100% at 0 µM, 16.6% at 0.1 µM, Figure 3B). Similar to the effect on phospho-S6, Dasatinib caused
marginal effects on phospho-4E-BP1 (Thr37/46 or Ser65) in either type of cells.
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For the phosphorylation of Src and p38 MAPK, we noticed that Dactolisib generated little effect
on all three cell types (100% at 0 µM, >95% at 0.1 µM, Figure 3C). On the contrary, Dasatinib showed
particularly strong inhibition on phosphorylation of Src and p38 MAPK in T cells: phospho-Src Tyr416
reduced from 100% to 31.5% at 0.1 µM, phospho-Src Tyr527 reduced from 100% to 14.2% at 0.1 µM, and
phospho-p38 MAPK Thr180/182 reduced from 100% to 50% at 0.1 µM (Figure 3C). Effect of Dasatinib
on phospho-Src Tyr416 and phospho-p38 MAPK Thr180/182 in PCa cells and Gr-MDSCs was moderate
to minimal, but its effect on phospho-Src Tyr527 in PCa cells and Gr-MDSCs was substantial (reduced
from 100% to 25.3% at 0.1 µM in PCa cells, and from 100% to 37% at 0.01 µM in Gr-MDSCs, Figure 3C).
To corroborate the results from RPPA, we detected the dysregulated proteins and PTMs by western
blot. Dactolisib strongly inhibited S6 phosphorylation at Ser235/236 and Ser240/244 in Gr-MDSCs and
PCa cells (Figure 4A,B). S6 and phospho-S6 were barely detectable in T cells (Figure 4C). Dactolisib also
suppressed 4E-BP1 phosphorylation at Thr37/46 and Ser65 in Gr-MDSCs and PCa cells (Figure 4A,B),
yet 4E-BP1 phosphorylation in T cells was largely resistant to Dactolisib treatment. In contrast to
Dactolisib, the effect of Dasatinib on phosphorylation of S6 or 4E-BP1 in all three cell types was
much weaker or essentially absent (Figure 4A–C). However, Dasatinib (but not Dactolisib) inhibited
p38 MAPK phosphorylation at Thr180/182, Src phosphorylation at both Tyr416 and Try527 and Lck
phosphorylation at both Tyr394 and Tyr505, preferentially in T cells (Figure 4C). As an internal control,
CD3ε remained unchanged in T cells by the drug treatments (Figure 4C). It is worth noting that the
moderate inhibitory effect of Dasatinib on Src phosphorylation in Gr-MDSCs and PCa cells was only
observed for Tyr527 but not Tyr416 (Figure 4A,B). Overall, these results validated the RPPA results
and supported (1) the selective downregulation of phospho-S6 and phospho-4E-BP1 by Dactolisib in
Gr-MDSCs and PCa cells, and (2) the preferential downregulation of phospho-Src and phospho-p38
MAPK by Dasatinib in T cells.
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2.4. Dactolisib, but not Dasatinib, Elicited Substantial Transcriptomic Alteration of Gr-MDSCs and
Downregulated Genes Associated with Mitochondrial Respiration
To provide a complementary view of the gene expression changes by Dactolisib and Dasatinib
treatment in Gr-MDSCs, we treated CRPC-derived Gr-MDSCs with DMSO (n = 4), Dactolisib (0.1 µM,
n = 2) or Dasatinib (0.1µM, n = 2) for 6 h before purifying the mRNA for microarray profiling. Differential
expression analysis identified more genes with altered expression by Dactolisib treatment (1733 genes
upregulated, 2663 genes downregulated, p < 0.05; 676 genes upregulated, 1414 downregulated, p <
0.01) than Dasatinib treatment (154 genes upregulated, 46 genes downregulated, p < 0.05; 11 genes
upregulated, 12 downregulated, p < 0.01) (Figure 5A,B, Figure S1A, Supplementary Tables S5 and S6).
To explore the functional consequence of the altered gene expression, each of the 4 lists of altered genes
(Dactolisib-upregulated, p < 0.01; Dactolisib-downregulated, p < 0.01; Dasatinib-upregulated, p < 0.05;
Dasatinib-downregulated, p < 0.05) were analyzed for Gene Ontology (GO) over-representation, KEGG
pathway enrichment and Reactome enrichment. Only the Dactolisib-downregulated genes showed
significantly enriched GO terms and pathways. The enriched GO terms were mainly associated with
mitochondrial functions, such as mitochondrial respiration chain complex assembly, ATP synthesis
coupled electron transport, and NADH dehydrogenase complex assembly (Figure 5C, Supplementary
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Table S7). Similarly, oxidative phosphorylation was the top-ranked enriched pathway in KEGG
analysis (Figure S1B, Supplementary Table S8), and respiratory electron transport/ATP synthesis
by chemiosmotic coupling was the top-ranked enriched pathway by Reactome analysis (Figure
S1C, Supplementary Table S9). No significant enrichment was found for Dactolisib-upregulated,
Dasatinib-upregulated, and Dasatinib-downregulated genes.
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Figure 5. Dactolisib, but not Dasatinib, downregulated mitochondrial respiration genes in
Gr-MDSCs based on microarray analysis. (A) p value distributions for differentially expressed
probes between Dactolisib and DMSO control, or between Dasatinib and DMSO control based
on unpaired t-test. (B) Volcano plots showing differentially expressed genes by Dactolisib or
Dasatinib treatment on Gr-MDSCs. Some of the most significantly altered genes are labeled.
Blue/Red: downregulated/upregulated genes by inhibitor treatment. (C) GO term over-representation
analysis of downregulated genes by Dactolisib treatment, highlighting the enrichment of genes
involved in mitochondrial respiration activity. BP: biological process; CC: cellular component; MF:
molecular function.
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3. Discussion
Our study interrogates the differential effect of Dactolisib and Dasatinib on PCa cells, T cells
and Gr-MDSCs isolated from the same mouse primary CRPC. Employing the power of RPPA, this
study reveals the unique protein expression patterns of the three cell types. Some of the features are
expected, such as higher Lck in T cells and higher E-cadherin, phospho-Akt and phospho-S6 in PCa
cells. The dramatically higher P-Cadherin level in Gr-MDSCs compared with T cells and PCa cells
is surprising and intriguing. As a calcium-dependent cell–cell adhesion glycoprotein, P-Cadherin
shares about 67% of homology with E-Cadherin, yet remains far less characterized [20]. P-Cadherin
is expressed by myoepithelial/basal cells in a heterogeneous manner in organs like the basal layer
of the epidermis, breast, prostate, and part of the digestive tract [20]. Normal hematopoietic cells
are not known to express P-Cadherin. Given that Gr-MDSCs massively dysregulate gene expression
relative to normal neutrophils [21,22], it will be important to investigate whether human Gr-MDSCs
also upregulate P-Cadherin and the role of P-Cadherin in the biological function of Gr-MSDCs. Once
validated, P-Cadherin may be a new surface marker and therapeutic target for Gr-MDSCs. P-Cadherin+
cells can be targeted for killing using P-Cadherin-targeted radioimmunotherapeutic FF-21101(90Y) [23]
or antibody-drug conjugates [24].
Upon the 2 h drug treatment, PCa cells, T cells and Gr-MDSCs all exhibit rather limited changes of
protein levels and protein phosphorylation levels. This result can be accounted for by two reasons: first,
among the proteins and PTMs identifiable by the 297 unique antibodies, Dactolisib and Dasatinib were
highly selective and only affected a few targets; second, the short drug incubation duration restricted
changes only to the direct targets and more broad secondary effects were not detected. The changes
caused by the two inhibitors on PCa cells, T cells and Gr-MDSCs highlight the specificity of Dactolisib
and Dasatinib: the dual PI3K/mTOR inhibitor Dactolisib dampened phospho-S6 and phospho-4E-BP1,
whereas the TKi Dasatinib attenuated phospho-Src and phospho-p38 MAPK.
The main significance of this study is that through the distinct regulation of the two drugs on
PCa cells, T cells and Gr-MDSCs, we can gain insights into the mechanism of action of Dactolisib and
Dasatinib and help explain why Dactolisib can, but Dasatinib cannot, cooperate with ICB therapy
in treating preclinical CRPC [16]. First, Dactolisib preferentially inhibited phospho-S6 (Ser235/236,
Ser240/244) in PCa cells and phospho-4E-BP1 (Thr37/46) in Gr-MDSCs (Figure 3A,B). Dactolisib
inhibits PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these enzymes [25].
mTOR is the key component of mTORC1 complex that promotes protein synthesis largely through the
phosphorylation of two effectors, p70 S6 kinase (S6K1, which further phosphorylates S6) and 4E-BP1 [26].
Previous studies demonstrate that S6K1 and 4E-BP1 can be dephosphorylated in different patterns by
the same mTORC1 inhibitor (e.g., rapamycin) in a cell type-dependent manner [27,28]. In the CPPSML
PCa cells, Pten deficiency leads to hyperactive PI3K/mTOR signaling [16,29], whereas for Gr-MDSCs,
several studies have established the essential role of PI3Kδ/γ signaling in the immunosuppressive
function [16,30,31]. Due to the differences in upstream activation mechanisms, it is conceivable
that mTORC1 in the two cell types elicits differential activation of S6K1 and 4E-BP1, which may
explain the differential response of phospho-S6 and phospho-4E-BP1 in the two cell types to the same
pan-PI3K inhibitor Dactolisib. The much more significant reduction of Thr37/46 phosphorylation of
4E-BP1 compared with Ser65 phosphorylation in Dactolisib-treated Gr-MDSCs is likely caused by the
hierarchical phosphorylation process of 4E-BP1, whereby phosphorylation of Thr37/46 is a priming
event for the subsequent phosphorylation of Ser65 [32,33]. It will be interesting for future experiments
to define the role of 4E-BP1 phosphorylation in the immunosuppressive function of Gr-MDSCs.
With these said, our validation studies with western blot still revealed substantial downregulation
of both phospho-S6 and phospho-4E-BP1 by Dactolisib treatment in Gr-MDSCs (Figure 4A), consistent
with our previous publication [16]. Moreover, at the transcriptomic level, Dactolisib treatment (but not
Dasatinib) on Gr-MDSCs caused an interesting downregulation of genes involved in the mitochondrial
electron transport chain (Figure 5C, Figure S1B,C). It is known that mTOR signaling coordinates energy
consumption by regulating mRNA translation and synthesis of nucleus-encoded mitochondria-related
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components of complexes I and V [34]. Specifically, mTORC1 controls mitochondrial activity and
biogenesis by selectively promoting translation of nucleus-encoded mitochondria-related mRNAs
via inhibition of 4E-BP [35]. A previous study demonstrated reprogrammed metabolism in
tumor-infiltrating MDSCs in various murine tumor models, whereby these cells upregulated fatty acid
uptake and β oxidation, mitochondrial biogenesis and oxygen consumption [36]. Inhibition of fatty
acid oxidation by etomoxir attenuated the immunosuppressive activity of MDSCs and synergized with
immunotherapy [36], similar to our observation of the synergistic anti-tumor efficacy of Dactolisib and
immunotherapy [16]. Collectively, these results suggest that a major effect of Dactolisib on Gr-MDSCs
is inhibition of mTOR and oxidative phosphorylation, which compromises fatty acid oxidation and
leads to loss of immunosuppression.
Dasatinib preferentially inhibited Src and p38 MAPK phosphorylation in T cells, providing
a molecular explanation for the effect of Dasatinib on diminishing T cells in the CRPC
microenvironment [16]. Src-family kinases Lck and Fyn in proximal T-cell receptor signal transduction
play critical roles in T-cell activation, differentiation, and tolerance [37]. Dasatinib inhibits Src, Lck
and Fyn [38]. While the RPPA platform did not have antibodies recognizing phospho-Lck, Fyn
or phospho-Fyn, the antibodies for Src and phospho-Src (Tyr527, Tyr416) provided surrogates for
evaluating the effects of Dasatinib on T cells as well as PCa cells and Gr-MDSCs. Src activity is
regulated by tyrosine phosphorylation at two sites, but with opposing effects [39]. Phosphorylation
at Tyr527 in the carboxy-terminal tail by Csk renders Src in a closed, inactive conformation. Upon
dephosphorylation of Tyr527, Src changes into an open conformation and self-phosphorylates Tyr416
to become activated [39]. Dasatinib reduced Tyr527 phosphorylation in all three cell types, yet only
reduced Tyr416 phosphorylation in T cells (Figure 3C, Figure 4C), suggesting complete loss of Src activity
preferentially in T cells. Additional validation experiments with western blot showed dampened
Lck phosphorylation by Dasatinib in T cells (Figure 4C), which further helps explain the depletion
of tumor-infiltrating T cells by a month-long Dasatinib treatment in the CPPSML CRPC model [16].
Moreover, Dasatinib preferentially inhibited the phosphorylating activation of p38 MAPK (Figure 3C,
Figure 4C), a protein with important roles in activating T cells especially CD4+ T cells to release
TNF-α [40,41]. These results collectively help explain the failure of Dasatinib to synergize with ICB in
treating CRPC [16]. Therefore, while Dasatinib may block MDSC expansion in certain scenarios [42,43],
its adverse effect on T cells [16,44] makes its application in combination immunotherapy unpromising.
Taken together, our studies highlight the advantage of using a targeted proteomics approach
such as RPPA to dissect the impact of inhibitors on primary tumor cells and immune cells. By
finding distinct protein expression patterns and differential sensitivity of protein phosphorylation to
Dactolisib and Dasatinib, our results offer some in-depth explanations on the molecular basis of the
success of Dactolisib/ICB combination and the failure of Dasatinib/ICB combination in the preclinical
CRPC model, and strengthen the idea of combining PI3K inhibitors and immunotherapy in treating
refractory malignancies. RPPA provides a robust and quick snapshot of some of the most important
proteins in cells. Nevertheless, an obvious limitation is that the number of antibodies is still low
compared with the entire proteome. Future studies employing mass spectrometry-based proteomics
and phosphoproteomics [45] will reveal the effect of targeted therapeutics on Gr-MDSCs in more
comprehensive and precise manners. A caveat of the study is that the 2 h treatment of various cells
in vitro for RPPA analysis may not represent what these cells experience in vivo when a patient is
treated with Dactolisib or Dasatinib. Therefore, conclusions drawn from these in vitro cell models with
short drug treatments should be further validated with specimens collected from possible clinical trials
that use Dactolisib or Dasatinib to treat patients with PCa.
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4. Materials and Methods
4.1. Mouse Model
PB-Cre+ PtenL/L p53L/L Smad4L/L mTmGL/+ LSL-LucL/+ (CPPSML) mice and the method to induce
CRPC in male mice were described previously [16]. Briefly, 8–12 weeks old males with correct genotype
verified by PCR-based genotyping were imaged by magnetic resonance imaging instrument Bruker
ICON (Bruker, Billerica, MA, USA) to quantify prostate tumor volume. Once the prostate tumor
reached 150 mm3, the mice were surgically castrated and switched to an enzalutamide-admixed diet for
4 weeks. Enzalutamide (MedKoo Biosciences, 201821, Morrisville, NC, USA) was admixed with Purina
5053 Chow at 50 mg drug/kg diet (Research Diets, Inc., New Brunswick, NJ, USA). After 4 weeks,
the mice were euthanized for isolating three types of cells. Mice were maintained in pathogen-free
conditions. All manipulations were approved by the Institutional Animal Care and Use Committee
(IACUC) of University of Texas MD Anderson Cancer Center (Protocol ID 1169, approved on Jan 26,
2015) and University of Notre Dame (Protocol ID 17-04-3809, approved on May 11, 2017).
4.2. Isolation of PCa Cells, Gr-MDSCs and T Cells
CPPSML male mice with CRPC induced were euthanized to harvest prostate tumors and
spleens. Prostate tumors were digested to single cells with Mouse Tumor Dissociation Kit (Miltenyi
Biotec, 130-096-730, Auburn, CA, USA). Primary PCa cells were isolated by FACS of GFP+ CD45−
viable cells and subsequently cultured for 2–3 passages in DMEM supplemented with 10% fetal
bovine serum (HyClone, GE Healthcare Life Sciences SH30396.03, Marlborough, MA, USA) and 1X
Penicillin-Streptomycin (Caisson Labs, PSL01, Smithfield, UT, USA) as adherent primary cells before
inhibitor treatment. Intratumoral Gr-MDSCs were isolated by first enriching for lymphocytes using
Lympholyte-M Cell Separation Media (Cederlane, CL5031, Burlington, ON, Canada) followed by
MACS-based isolation using a Mouse MDSC Isolation Kit (Miltenyi Biotec, 130-094-538, Auburn,
CA, USA). From the same mice, total T cells were isolated from the spleens using Mouse Pan T Cell
Isolation Kit II (Miltenyi Biotec, 130-095-130, Auburn, CA, USA). Gr-MDSCs and T cells were plated
in RPMI-1640 supplemented with 10% fetal bovine serum (HyClone, GE Healthcare Life Sciences
SH30396.03, Marlborough, MA, USA) and 1X Penicillin-Streptomycin (Caisson Labs, PSL01, Smithfield,
UT, USA) and treated with inhibitors immediately.
4.3. Inhibitor Treatment
Gr-MDSCs, T cells and PCa cells isolated and plated in respective medium as described above
were added with DMSO, Dactolisib and Dasatinib at different concentrations for 2 h in a standard
tissue culture incubator with 37 ◦C and 5% CO2. Next, the cells were washed with inhibitor-free
and serum-free medium once and harvested as pellet and stored at −80 ◦C before submitting to the
RPPA analysis.
4.4. Reverse Phase Protein Array (RPPA)
RPPA was conducted by the RPPA Core Facility at MD Anderson Cancer Center following
the standard protocols at the facility, the details of which can be found on the core facility
website (www.mdanderson.org/research/research-resources/core-facilities/functional-proteomics-rppa-
core.html). The dataset returned from the facility included raw data in log2 value and normalized data
in linear value.
4.5. Western Blot
For western blot analysis, cell lysates prepared by the RPPA core were used following the procedure
as previously described [16]. Primary antibodies were mostly purchased from Cell Signaling Technology
(CST, Danvers, MA, USA), including S6 (CST 2217), phospho-S6 Ser235/236 (CST 4858), phospho-S6
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Ser240/244 (CST 5364), 4E-BP1 (CST 9644), phospho-4E-BP1 Thr 37/46 (CST 2855), phospho-4E-BP1
Ser65 (CST 9451), Src (CST 2109), phospho-Src Tyr416 (CST 6943), phospho-Src Tyr527 (CST 2105), p38
MAPK (CST 9212), phospho-P38 MAPK Thr180/182 (CST 4511), Lck (CST 2787), phospho-Lck Tyr394
(Thermo Fisher, PA5-37628, Waltham, MA, USA), phospho-Lck Tyr505 (CST 2751), CD3ε (CST 4443),
β-actin (Santa Cruz sc-47778). Secondary antibodies included HRP-linked anti-mouse IgG (CST 7076),
HRP-linked anti-rat IgG (CST 7077) and HRP-linked anti-rabbit IgG (CST 7074). Clarity Max western
ECL substrate (Bio-Rad, Hercules, CA, USA) was used for chemiluminescence detection.
4.6. Microarray and Analysis
RNA was purified from inhibitor treated primary Gr-MDSCs (6 h) using RNeasy Mini Kit (Qiagen,
Germantown, MD, USA). Microarray (Affymetrix Mouse Genome 430 2.0 Array) was conducted
by the Sequencing and Microarray Facility at MD Anderson Cancer Center following the facility’s
standard procedure. The data were analyzed in RStudio, including oligo 1.50.0 package [46] and
arrayQualityMetrics 3.42.0 package [47] used for quality control and calibration, ArrayExpress 1.46.0
package [48] and mouse4302.db 3.2.3 package used for probe annotation, and limma 3.42.2 package [49]
was used for differential expression analysis. p value of 0.05 or 0.01 by unpaired t-test was used as
threshold of significantly upregulated or downregulated genes by Dactolisib or Dasatinib treatment,
respectively. For pathway analysis, the gene lists were imported to RStudio with clusterProfiler 3.14.3
package [50] used for GO term and KEGG pathway analysis and ReactomePA 1.30.0 package [51]
used for Reactome analysis. The microarray raw and normalized data were deposited to NCBI GEO
database with accession number GSE146083.
4.7. Statistical Analysis
Heatmaps were constructed with median-centered log2 values in Figure 1 and normalized log2
values in Figure 2 using package pheatmap 1.0.12 in RStudio. Graphs in Figure 3 were generated using
normalized linear values. Significance test in Figures 1C and 5B was by unpaired t-test in RStudio.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/7/
2337/s1. Supplementary materials include Figure S1. Microarray analysis of Gr-MDSCs. (A) Adjusted-P value
distributions for differentially expressed probes between Dactolisib and DMSO control, or between Dasatinib and
DMSO control based on unpaired t-test, p values adjusted by the Benjamini and Hochberg method. (B) KEGG
pathway enrichment analysis of downregulated genes by Dactolisib treatment. (C) Reactome enrichment analysis
of downregulated genes by Dactolisib treatment; Table S1. RPPA data normalized in linear values, generated
by the RPPA Core Facility; Table S2. Differential RPPA protein levels between MDSC and T cells (unpaired
student t-test); Table S3. Differential RPPA protein levels between MDSC and PCa cells (unpaired student t-test);
Table S4. Differential RPPA protein levels between PCa cells and T cells (unpaired student t-test); Table S5.
Microarray gene expression fold changes and p values of Dactolisib vs. control treated MDSCs; Table S6.
Microarray gene expression fold changes and p values of Dasatinib vs. control treated MDSCs; Table S7. GO term
over-representation enrichment result of downregulated gene in Dactolisib treated MDSCs based on microarray
data; Table S8. KEGG pathway enrichment result of downregulated gene in Dactolisib treated MDSCs based on
microarray data; Table S9. Reactome reactions enrichment result of downregulated gene in Dactolisib treated
MDSCs based on microarray data.
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Abbreviations
4E-BP1 eukaryotic translation initiation factor 4E binding protein 1
ARID1A AT rich interactive domain 1A
ATP adenosine triphosphate
CD3ε T-cell surface glycoprotein CD3 epsilon chain
CPPSML PB-Cre+ PtenL/L p53L/L Smad4L/L mTmGL/+ LSL-LucL/+
CRPC castration-resistant prostate cancer
Csk C-terminal Src kinase
CTL cytotoxic T lymphocyte
CTLA4 cytotoxic-T-lymphocyte-associated protein 4
eIF4G eukaryotic translation initiation factor 4G
FACS fluorescence-activated cell sorting
Fyn tyrosine-protein kinase Fyn
GO Gene Ontology
Gr-MDSC granulocytic myeloid-derived suppressor cell
ICB immune checkpoint blockade
KEGG Kyoto Encyclopedia of Genes and Genomes
Lck lymphocyte protein tyrosine kinase
MACS magnetic-activated cell sorting
MAPK mitogen-activated protein kinase
mTOR mechanistic target of rapamycin kinase
mTORC1 mTOR Complex I
NDRG1 N-myc downstream regulated gene 1
PCa prostate cancer
PD1 programmed cell death 1
PD-L1 programmed cell death 1 ligand 1
PI3K phosphoinositide-3-kinase
PTM post-translational modification
RPPA Reverse Phase Protein Array
S6K1 ribosomal protein S6 kinase
Src Rous sarcoma oncogene
TAZ tafazzin
TKi tyrosine kinase inhibitor
TNF-α tumor necrosis factor alpha
YAP yes-associated protein
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